Ipamorelin and CJC-1295 Peptide Combination Pack: Advance Your Research
Explore the synergistic potential of growth hormone research with our exclusive combination pack featuring CJC 1295 and Ipamorelin peptides. Tailored to meet the demands of cutting-edge scientific exploration, this pack offers exceptional purity, potency, and reliability for laboratory use only.
Ipamorelin
Mechanism of Action:
Ipamorelin is a pentapeptide known for its ability to stimulate the pituitary gland to release growth hormone. It operates by interacting with growth hormone secretagogue receptors, triggering a cascade of biological events leading to elevated growth hormone levels. Ipamorelin is classified as a Growth Hormone-Releasing Peptide (GHRP), recognized for its capacity to increase levels of growth hormone.
Selective Effects:
Ipamorelin exerts its effects primarily on growth hormone release, with minimal impact on other hormones such as thyroid-stimulating hormone, luteinizing hormone, and prolactin.
Ipamorelin Product Specifications:
CAS Number: 170851-70-4
Formula: C38H49N9O5
Sequence: Aib-His-D-2-Nal-D-Phe-Lys-NH2
Molar Mass: 711.85 g/mol
Half life: 2 hours
Class: Peptide
Storage: Keep refrigerated upon reconstitution.
- Lyophilized sample in sterile glass vial.
- Minimum 99% pure.
- 5mg Ipamorelin per vial.
- Diluent and laboratory supplies not included.
CJC-1295
Mechanism of Action:
CJC-1295 mimics natural Growth Hormone Releasing Hormones (GHRH) in the body, effectively binding to growth hormone-releasing hormone receptors in the anterior pituitary gland. This interaction stimulates the production and release of growth hormones into systemic circulation, leading to sustained increased levels for an extended period.
Extended Half-life:
CJC-1295 boasts a prolonged duration of action compared to conventional peptides, thanks to the inclusion of Drug Affinity Complex (DAC), which extends stability and ensures sustained stimulation of growth hormone production.
CJC-1295 DAC Specifications:
CAS Number: 863288-34-0
Formula: C152H252N44O42
Sequence: Tyr-D-Ala-Asp-Ala-Ile-Phe-Thr-Gln-Ser-Tyr-Arg-Lys-Val-Leu-Ala-Gln-Leu-Ser-Ala- Arg-Lys-LeuLeu-Gln-Asp-Ile-Leu-Ser-Arg-Lys
Molar Mass: 3367.9 g/mol
Half life: 6-8 days
Class: Peptide
Storage: Keep refrigerated upon reconstitution.
- Lyophilized sample in sterile glass vial.
- Minimum 99% pure.
- 5mg CJC-1295 DAC per vial.
- Diluent and laboratory supplies not included.
FAQs On Ipamorelin and CJC-1295 DAC
What are the key features of Ipamorelin and CJC-1295?
Ipamorelin promotes growth hormone release with minimal impact on other hormones, while CJC-1295 sustains increased growth hormone levels for an extended period.
How should Ipamorelin and CJC-1295 be stored?
Both peptides should be refrigerated upon reconstitution to maintain potency.
What research applications are suitable for Ipamorelin and CJC-1295?
These peptides are ideal for studying growth hormone regulation, metabolic processes, and therapeutic interventions in various medical conditions.
Why Choose Sports Technology Labs?
At Sports Technology Labs, we are dedicated to providing researchers with top-quality peptides for laboratory use. Our combination pack of Ipamorelin and CJC-1295 undergoes stringent testing by US-based laboratories to ensure a minimum purity of 98%. Enjoy free shipping on orders exceeding $149, with options for expedited delivery.
Subscribe to our email list for a 10% discount and an additional 10% off when paying with cryptocurrency. Trust Sports Technology Labs for superior quality, fast shipping, and outstanding customer service.
For inquiries about our combination pack or peptide stacks or assistance with your research needs, please contact us. Experience the forefront of scientific discovery with Sports Technology Labs today.
Scientific References:
1. Raun K, Hansen BS, Johansen NL, Thøgersen H, Madsen K, Ankersen M, Andersen PH. Ipamorelin, the first selective growth hormone secretagogue. Eur J Endocrinol. 1998 Nov;139(5):552-61. doi: 10.1530/eje.0.1390552. PMID: 9849822.
2. Aagaard NK, Grøfte T, Greisen J, Malmlöf K, Johansen PB, Grønbaek H, Ørskov H, Tygstrup N, Vilstrup H. Growth hormone and growth hormone secretagogue effects on nitrogen balance and urea synthesis in steroid treated rats. Growth Horm IGF Res. 2009 Oct;19(5):426-31. doi: 10.1016/j.ghir.2009.01.001. Epub 2009 Feb 23. PMID: 19231263.
3. Andersen NB, Malmlöf K, Johansen PB, Andreassen TT, Ørtoft G, Oxlund H. The growth hormone secretagogue ipamorelin counteracts glucocorticoid-induced decrease in bone formation of adult rats. Growth Horm IGF Res. 2001 Oct;11(5):266-72. doi: 10.1054/ghir.2001.0239. PMID: 11735244.
4. Svensson J, Lall S, Dickson SL, Bengtsson BA, Rømer J, Ahnfelt-Rønne I, Ohlsson C, Jansson JO. The GH secretagogues ipamorelin and GH-releasing peptide-6 increase bone mineral content in adult female rats. J Endocrinol. 2000 Jun;165(3):569-77. doi: 10.1677/joe.0.1650569. PMID: 10828840.
5. Adeghate E, Ponery AS. Mechanism of ipamorelin-evoked insulin release from the pancreas of normal and diabetic rats. Neuro Endocrinol Lett. 2004 Dec;25(6):403-6. PMID: 15665799.
6. Fowkes MM, Lalonde T, Yu L, Dhanvantari S, Kovacs MS, Luyt LG. Peptidomimetic growth hormone secretagogue derivatives for positron emission tomography imaging of the ghrelin receptor. Eur J Med Chem. 2018 Sep 5;157:1500-1511. doi: 10.1016/j.ejmech.2018.08.062. Epub 2018 Aug 23. PMID: 30282322.
7. Beck DE, Sweeney WB, McCarter MD; Ipamorelin 201 Study Group. Prospective, randomized, controlled, proof-of-concept study of the Ghrelin mimetic ipamorelin for the management of postoperative ileus in bowel resection patients. Int J Colorectal Dis. 2014 Dec;29(12):1527-34. doi: 10.1007/s00384-014-2030-8. Epub 2014 Oct 21. PMID: 25331030.
8. Greenwood-Van Meerveld B, Tyler K, Mohammadi E, Pietra C. Efficacy of ipamorelin, a ghrelin mimetic, on gastric dysmotility in a rodent model of postoperative ileus. J Exp Pharmacol. 2012 Oct 19;4:149-55. doi: 10.2147/JEP.S35396. PMID: 27186127; PMCID: PMC4863553.
9. Ipamorelin Peptide: Exploring its Potential in Growth Hormone Stimulation and Health. Peptide Information (2023).
10. Sackmann-Sala, L., Ding, J., Frohman, L. A., & Kopchick, J. J. (2009). Activation of the GH/IGF-1 axis by CJC-1295, a long-acting GHRH analog, results in serum protein profile changes in normal adult subjects. Growth Hormone & IGF Research, 19(6), 471-477.
11. Knoop, A., Thomas, A., Fichant, E., Delahaut, P., Schänzer, W., & Thevis, M. (2016). Qualitative identification of growth hormone-releasing hormones in human plasma by means of immunoaffinity purification and LC-HRMS/MS. Analytical and Bioanalytical Chemistry, 408, 3145-3153.
12. Van Hout, M. C., & Hearne, E. (2016). Netnography of female use of the synthetic growth hormone CJC-1295: pulses and potions. Substance Use & Misuse, 51(1), 73-84.
13. Alba, M., Fintini, D., Sagazio, A., Lawrence, B., Castaigne, J. P., Frohman, L. A., & Salvatori, R. (2006). Once-daily administration of CJC-1295, a long-acting growth hormone-releasing hormone (GHRH) analog, normalizes growth in the GHRH knockout mouse. American Journal of Physiology-Endocrinology and Metabolism, 291(6), E1290-E1294.
14. McDonald J, Lambert DG. Drug-receptor interactions in anaesthesia. BJA Educ. 2022 Jan;22(1):20-25. doi: 10.1016/j.bjae.2021.07.009. Epub 2021 Oct 14. PMID: 34992797; PMCID: PMC8703152.
